Asset profile
LY03020
Small molecule
Evidence outlook · lead readout
NCT06556966 · Schizophrenia, Alzheimer's Disease Psychosis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06556966: Participants were randomly assigned to LY03020 or a placebo, and the study kept participants, care providers and investigators blinded to the assignment, which is a solid safety-testing design. However, it was built to measure side-effect rates and drug levels rather than any disease-related outcome, and results are not posted yet, so there is no read on how the drug performed.
Also in development:Alzheimer's Disease · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
December 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.